Teriparatide in the treatment of osteoporosis

American Journal of Health-System Pharmacy

Volumn 65, Issue 6, 2008, Pages 532-539

  Stroup, Jeffrey ^a   Kane, Michael P ^b   Abu Baker, Asim M ^c  

^a OKLAHOMA STATE UNIVERSITY   (United States)

^b ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^c ST JOHN FISHER COLLEGE   (United States)

Author keywords

Costs; Fractures; Hormones; Mechanism of action; Osteoporosis; Post menopause; Teriparatide; Toxicity

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; BONE DENSITY CONSERVATION AGENT; GLUCOCORTICOID;

CLINICAL TRIAL; DIZZINESS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FRACTURE; HEADACHE; HUMAN; HYPERCALCEMIA; INJECTION SITE PAIN; LEG CRAMP; NAUSEA; OSTEOPOROSIS; PHARMACIST; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; SWELLING; THORAX PAIN; URTICARIA; BONE DENSITY; DRUG COMBINATION; DRUG EFFECT; HORMONE SUBSTITUTION; UNITED STATES;

BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; FRACTURES, BONE; GLUCOCORTICOIDS; HORMONE REPLACEMENT THERAPY; HUMANS; OSTEOPOROSIS; TERIPARATIDE; UNITED STATES;

EID: 41049084972     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp070171     Document Type: Review

References (57)

1. Siris E, Miller P, Barrett-Connor E et al. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA. 2001; 286:2815-26.
2. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001; 285:785-95.
3. World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: report of a WHO study group. World Health Organ Tech Rep Ser. 1994; 843:1-129.
4. National Osteoporosis Foundation. Fast facts. www.nof.org/osteoporosis/ diseasefacts.htm (accessed 2007 Feb 22).
5. National Osteoporosis Foundation. America's bone health: the state of osteoporosis and low bone mass, September 2004. www.nof.org/advocacy/prevalence/ (accessed 2007 Feb 27).
6. Center JR, Nguyen TV, Schneider D et al. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet. 1999; 353:878-82.
7. Hodgson SF, Watts NB, Bilezikian JP et al., for the AACE Osteoporosis Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract. 2003; 9:544-64.
8. U.S. Department of Health and Human Services. Bone health and osteoporosis: a report of the Surgeon General (2004). www.hhs.gov/ surgeongeneral/library/bonehealth (accessed 2007 Feb 27).
9. Seeman E, Delmas PD. Bone quality - the material and structural basis of bone strength and fragility. N Engl J Med. 2006; 354:2250-61.
10. Forteo (teriparatide) package insert. Indianapolis, IN: Eli Lilly and Co.; 2004.
11. Neer RM, Arnaud CD, Zanchetta JR et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001; 344:1434-41.
12. Thomas T. Intermittent parathyroid hormone therapy to increase bone formation. Joint Bone Spine. 2006; 73:262-9.
13. Girotra M, Rubin MR, Bilezikian JP. The use of parathyroid hormone in the treatment of osteoporosis. Rev Endocr Metab Disord. 2006; 7:113-21.
14. McClung MR, San Martin J, Miller PD et al. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med. 2005; 165:1762-8.
15. Body JJ, Gaich GA, Scheele WH et al. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2002; 87:4528-35.
16. Orwoll ES. Osteoporosis in men. Endocrinol Metab Clin North Am. 1998; 27:349-67.
17. National Institute of Arthritis and Musculoskeletal and Skin Diseases. Osteoporosis overview, May 2006. www.niams.nih.gov/bone/hi/overview.htm (accessed 2006 Aug 2).
18. Orwoll E, Scheele WH, Paul S et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone mineral density in men with osteoporosis. J Bone Miner Res. 2003; 18:9-17.
19. Kaufman JM, Orwoll E, Goemaere S et al. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int. 2005; 16:510-6.
20. Finkelstein JS, Hayes A, Hunzelman JL et al. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med. 2003; 349:1216-26.
21. Lane NE, Sanchez S, Modin GW et al. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. J Clin Invest. 1998; 102:1627-33.
22. Lane NE, Sanchez S, Modin GW et al. Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial. J Bone Miner Res. 2000; 15:944-51.
23. Chavassieux PM, Arlot ME, Reda C et al. Histomorphometric assessment of long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest. 1997; 100:1475-80.
24. Porras AG, Holland SD, Gertz BJ. Pharmacokinetics of alendronate. Clin Pharmacokinet. 1999; 36:315-28.
25. Tonino RP, Meunier PJ, Emkey R et al. Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group. J Clin Endocrinol Metab. 2000; 85:3109-15.
26. Jilka RL, Weinstein RS, Bellido T et al. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest. 1999; 104:439-46.
27. Dobnig H, Turner RT. Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. Endocrinology. 1995; 136:3632-8.
28. Onyia JE, Bidwell J, Herring J et al. In vivo, human parathyroid hormone fragment (hPTH 1-34) transiently stimulates immediate early response gene expression, but not proliferation, in trabecular bone cells of young rats. Bone. 1995; 17:479-84.
29. Finkelstein JS, Leder BZ, Burnett SM et al. Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men. J Clin Endocrinol Metab. 2006; 91:2882-7.
30. Ettinger B, San Martin J, Crans G et al. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res. 2004; 19:745-51.
31. Deal C, Omizo M, Schwartz EN et al. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. J Bone Miner Res. 2005; 20:1905-11.
32. Ste.-Marie LG, Schwartz SL, Hossain A et al. Effect of teriparatide [rhPTH(1-34)] on BMD when given to postmenopausal women receiving hormone replacement therapy. J Bone Miner Res. 2006; 21:283-91.
33. Hodsman AB, Bauer DC, Dempster DW et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev. 2005; 26:688-703.
34. Gold DT, Pantos BS, Masica DN et al. Initial experience with teriparatide in the United States. Curr Med Res Opin. 2006; 22:703-8.
35. Stroup J, Kane MP, Busch RS. Pharmacist-run teriparatide clinic. Am J Health-Syst Pharm. 2003; 60:2247-9.
36. Miller PD, Bilezikian JP, Deal C et al. Clinical use of teriparatide in the real world: initial insights. Endocr Pract. 2004; 10:139-48.
37. Vahle JL, Sato M, Long GG et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human study. Toxicol Pathol. 2002; 30:312-21.
38. Vahle JL, Long GG, Sandusky G et al. Bone neoplasms in F344 rats given teriparatide [rhPTH (1-34)] are dependent on duration of treatment and dose. Toxicol Pathol. 2004; 32:426-38.
39. Harper KD, Krege JH, Marcus R et al. Comments on initial experience with teriparatide in the United States. Curr Med Res Opin. 2006; 22:1927. Letter.
40. National Cancer Institute Surveillance Research Program. SEER Stat software version 6.1.4. www.seer.cancer.gov/seerstat (accessed 2007 Mar 1).
41. Chen P, Miller PD, Delmas PD et al. Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. J Bone Miner Res. 2006; 21:1785-90.
42. Zanchetta JR, Bogado CE, Ferretti JL et al. Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis. J Bone Miner Res. 2003; 18:539-43.
43. Jiang Y, Zhao JJ, Mitlak BH et al. Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res. 2003; 18:1932-41.
44. Dempster DW. The contribution of trabecular architecture to cancellous bone quality. J Bone Miner Res. 2000; 15:20-3.
45. Gonnelli S, Martini G, Caffarelli S et al. Teriparatide's effects on quantitative ultrasound parameters and bone density in women with established osteoporosis. Osteoporos Int. 2006; 17:1524-31.
46. Eastell R, Krege JH, Chen P et al. Development of an algorithm for using PINP to monitor treatment of patients with teriparatide. Curr Med Res Opin. 2006; 22:61-6.
47. Lindsay R, Scheele WH, Neer R et al. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med. 2004; 164:2024-30.
48. Prince R, Sipos A, Hossain A et al. Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. J Bone Miner Res. 2005; 20:1507-13.
49. Miller PD, Shergy WJ, Body J et al. Longterm reduction of back pain risk in women with osteoporosis treated with teriparatide compared with alendronate. J Rheumatol. 2005; 32:1556-62.
50. Kurland ES, Heller SL, Diamond B et al. The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone (1-34)]. Osteoporos Int. 2004; 15:992-7.
51. Fleming T, ed. Drug topics red book. Montvale, NJ: Thomson PDR; 2005.
52. Liu H, Michaud K, Nayak S et al. The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis. Arch Intern Med. 2006; 166:1209-17.
53. Lundkvist J, Johnell O, Cooper C et al. Economic evaluation of parathyroid hormone (PTH) in the treatment of osteoporosis in postmenopausal women. Osteoporos Int. 2006; 17:201-11.
54. MacLaughlin EJ, MacLaughlin AA, Snella KA et al. Osteoporosis screening and education in community pharmacies using a team approach. Pharmacotherapy. 2005; 25:379-86.
55. Naunton M, Peterson GM, Jones G. Pharmacist-provided quantitative heel ultrasound screening for rural women at risk of osteoporosis. Ann Pharmacother. 2006; 40:38-44.
56. Stroup JS, Rivers SM, Abu-Baker AM et al. Two year bone mass density and T-score changes in a pharmacist-run teriparatide clinic. Pharmacotherapy. 2007; 27:779-88.
57. Saag KG, Shane E, Boonen S et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007; 357:2028-39.